How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

ID6221 nemolizumab atopic dermatitis DG to PM for consultation [NoCON] indev.docx

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about nemolizumab

Marketing authorisation indication

2.1

Nemolizumab (Nemluvio, Galderma) is indicated for 'the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy'.

Price

2.3

The list price of nemolizumab is £2,257 per 30 mg unit (company submission).

2.4

The company has a commercial arrangement, which would have applied if nemolizumab had been recommended.

Comments panel open